



Curis, Inc.
Investor Relations Department
4 Maguire Road
Lexington, MA 02421
United States

[Visit IR website](#)
[Sign-up for email alerts](#)

NASDAQ: CRIS

| | |
|---------------|----------------------------|
| Last Trade: | 1.71 |
| Trade Time: | 4:00 PM ET May 24, 2017 |
| Change: | 0.00 (0.000%) |
| Day Range | N/A - N/A |
| 52-Week Range | 1.47 - 3.72 |
| Volume | N/A |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. In expanding its drug development efforts in the field of cancer through its proprietary targeted cancer programs, Curis is building upon its previous experiences in targeting signaling pathways for the development of next generation targeted cancer therapies. For more information, visit Curis' website at www.curis.com.... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- May 25, 2017*
[Curis Announces Presentations Related to CA-170 and CUDC-907 at 2017 ASCO Annual Meeting](#)
- May 4, 2017*
[Curis Reports First Quarter 2017 Financial Results](#)
- Apr 28, 2017*
[Curis to Release First Quarter 2017 Financial Results and Hold Conference Call on May 4, 2017](#)
- Apr 5, 2017*
[Curis Reports Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- Mar 30, 2017*
[Curis to Present Preclinical Data on IRAK4 Kinase Inhibitor CA-4948 at AACR Annual Meeting](#)

Financials [\[View all \]](#)

- [First Quarter Financial Results](#)
- Mar 9, 2017*
[Annual Report \(10-K\)](#)
- Apr 4, 2017*
[Proxy Statement \(DEF 14A\)](#)
- May 4, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 3, 2016*
[Quarterly Report \(10-Q\)](#)
- Aug 4, 2016*
[Quarterly Report \(10-Q\)](#)